Madame Bioscience PCL (BKK:MADAME)
Thailand · Delayed Price · Currency is THB 0.1300
+0.0100 (8.33%)
At close: Feb 5, 2026
Madame Bioscience PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,612 | 2,123 | 2,302 | 2,228 | 1,862 | 1,517 | |
Revenue Growth (YoY) | -25.13% | -7.78% | 3.35% | 19.61% | 22.79% | 29.43% |
Cost of Revenue | 1,304 | 1,763 | 2,006 | 2,146 | 1,561 | 1,224 |
Gross Profit | 307.34 | 359.99 | 296.44 | 81.33 | 301.34 | 292.71 |
Selling, General & Admin | 441.85 | 338.05 | 484.03 | 511.38 | 415 | 354.12 |
Other Operating Expenses | -493.23 | -19.91 | -21.41 | -44.62 | -3.56 | -14.38 |
Operating Expenses | -48.9 | 318.01 | 462.7 | 466.76 | 411.44 | 339.74 |
Operating Income | 356.24 | 41.98 | -166.26 | -385.44 | -110.1 | -47.03 |
Interest Expense | -36.7 | -50.94 | -61.11 | -42.13 | -10.56 | -8.97 |
Interest & Investment Income | 0.36 | 0.36 | 1 | 0.54 | 0.1 | 0.21 |
Currency Exchange Gain (Loss) | 1.99 | 1.99 | 4.49 | 8.35 | 5.92 | - |
EBT Excluding Unusual Items | 321.89 | -6.6 | -221.88 | -418.67 | -114.64 | -55.79 |
Impairment of Goodwill | - | - | -187.97 | -26.87 | -26.02 | - |
Gain (Loss) on Sale of Investments | -98.01 | -98.01 | - | - | - | -0.22 |
Gain (Loss) on Sale of Assets | 0.64 | 0.64 | 0.86 | 1.39 | 32.33 | 0.36 |
Asset Writedown | -0.01 | - | - | - | -103.9 | - |
Other Unusual Items | -225.96 | -225.96 | -0.66 | - | - | - |
Pretax Income | -1.45 | -329.94 | -409.66 | -444.07 | -187.53 | -55.65 |
Income Tax Expense | 2.8 | -0.76 | 2.8 | -5.99 | -21.27 | 2.42 |
Earnings From Continuing Operations | -4.26 | -329.18 | -412.45 | -438.08 | -166.26 | -58.07 |
Earnings From Discontinued Operations | 0.04 | 0.04 | -0.85 | 1.22 | -0.37 | 0.45 |
Net Income to Company | -4.22 | -329.14 | -413.31 | -436.86 | -166.63 | -57.62 |
Minority Interest in Earnings | -2.19 | -2.9 | 7.5 | 14.55 | 14.19 | -1.09 |
Net Income | -6.41 | -332.04 | -405.81 | -422.31 | -152.43 | -58.71 |
Net Income to Common | -6.41 | -332.04 | -405.81 | -422.31 | -152.43 | -58.71 |
Shares Outstanding (Basic) | 3,650 | 3,105 | 3,076 | 2,999 | 1,999 | 1,902 |
Shares Outstanding (Diluted) | 3,650 | 3,105 | 3,076 | 2,999 | 1,999 | 1,902 |
Shares Change (YoY) | 18.54% | 0.93% | 2.57% | 50.07% | 5.07% | 0.17% |
EPS (Basic) | -0.00 | -0.11 | -0.13 | -0.14 | -0.08 | -0.03 |
EPS (Diluted) | -0.00 | -0.11 | -0.13 | -0.14 | -0.08 | -0.03 |
Free Cash Flow | 60.95 | 211.62 | 32.37 | -307.46 | -304.86 | -194.31 |
Free Cash Flow Per Share | 0.02 | 0.07 | 0.01 | -0.10 | -0.15 | -0.10 |
Gross Margin | 19.07% | 16.96% | 12.88% | 3.65% | 16.18% | 19.30% |
Operating Margin | 22.11% | 1.98% | -7.22% | -17.30% | -5.91% | -3.10% |
Profit Margin | -0.40% | -15.64% | -17.63% | -18.96% | -8.19% | -3.87% |
Free Cash Flow Margin | 3.78% | 9.97% | 1.41% | -13.80% | -16.37% | -12.81% |
EBITDA | 389.03 | 110.97 | -81.76 | -309.71 | -35.37 | 38.2 |
EBITDA Margin | 24.14% | 5.23% | -3.55% | -13.90% | -1.90% | 2.52% |
D&A For EBITDA | 32.8 | 68.98 | 84.49 | 75.73 | 74.74 | 85.22 |
EBIT | 356.24 | 41.98 | -166.26 | -385.44 | -110.1 | -47.03 |
EBIT Margin | 22.11% | 1.98% | -7.22% | -17.30% | -5.91% | -3.10% |
Revenue as Reported | - | - | - | 2,228 | 1,862 | 1,517 |
Advertising Expenses | - | 3.14 | 80.99 | 14.79 | 16.14 | 8.85 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.